Literature DB >> 15227074

Neuroleptanalgesia in acute myocardial infarction.

A Balvanera1, J L Robledo, A E de los Monteros.   

Abstract

Neuroleptanalgesia describes a state of sedated analgesia produced by the administration of the tranquilizer, droperidol, and the potent narcotic, fentanyl, in combination. This combination of drugs was administered intravenously to effect neuroleptanalgesia in the early treatment of eight patients with acute anterior transmural myocardial infarction. Criteria for inclusion in the study were (1) persistent ischemic pain, (2) ST segment elevation of 0.3 or more mV in at least two standard precordial leads, (3) a heart rate of 80 or more beats per minute, (4) a mean arterial pressure of 75 or more mm Hg, and (5) a cardiac index of 2.0 L/min/m(2). Within 30 minutes of the administration of the drugs, all patients were relieved of pain and emotional stress. The sum of ST segment elevation from leads V(1) through V(6) (sigmaST(6)) and the average ST elevation over the precordium (ST) decreased significantly by 57% and 56%, respectively. At the same time, there was a significant reduction in heart rate (from 112 +/- 17 to 86 +/- 8 beats per minute), mean arterial pressure (from 100 +/- 7 to 82 +/- 4 mm Hg), and pulmonary arterial wedge pressure (from 17 +/- 7 to 12 +/- 2 mm Hg). The cardiac index increased from 2.25 +/- 0.22 to 2.40 +/- 0.07 L/min/m(2). Two hours later the hemodynamic parameters had returned to control levels, but the beneficial effect on myocardial injury persisted. Thus neuroleptanalgesia in the early hours of myocardial infarction can reduce preload, afterload, oxygen demand, and eventually the infarct size without depressing myocardial function.

Entities:  

Year:  1984        PMID: 15227074      PMCID: PMC341698     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  14 in total

1.  High dose fentanyl anesthesia for coronary artery surgery: plasma fentanyl concentrations and influence of nitrous oxide on cardiovascular responses.

Authors:  J K Lunn; T H Stanley; J Eisele; L Webster; A Woodward
Journal:  Anesth Analg       Date:  1979 Sep-Oct       Impact factor: 5.108

2.  Neuroleptanaesthesia for major surgery. Experience with 500 cases.

Authors:  M Morgan; J Lumley; I D Gillies
Journal:  Br J Anaesth       Date:  1974-04       Impact factor: 9.166

3.  [Analgesic effects and hemodynamic and respiratory repercussions of the fentanyl-droperidol combination in the acute stage of myocardial infarction].

Authors:  P Vermeire; P van den Bogaert; L Bossaert; G Heyndrickx; J P van Durme; R Pannier
Journal:  Arch Mal Coeur Vaiss       Date:  1973-04

4.  A new technique for measurement of cardiac output by thermodilution in man.

Authors:  W Ganz; R Donoso; H S Marcus; J S Forrester; H J Swan
Journal:  Am J Cardiol       Date:  1971-04       Impact factor: 2.778

5.  Neuroleptanalgesia II in recent myocardial infarction.

Authors:  J Luczak; K Brodzińska; A Skubiszyńska; W Szmydt
Journal:  Pol Med J       Date:  1969

6.  Usefulness and limitations of the rate of rise of intraventricular pressure (dp-dt) in the evaluation of myocardial contractility in man.

Authors:  D T Mason
Journal:  Am J Cardiol       Date:  1969-04       Impact factor: 2.778

7.  Neuroleptanalgesia in the treatment of acute myocardial infarction.

Authors:  E Riss; S Hemli; E Abinader
Journal:  Isr J Med Sci       Date:  1969 Jul-Aug

8.  Hemodynamic and ventilatory responses to fentanyl, fentanyl-droperidol, and nitrous oxide in patients with acquired valvular heart disease.

Authors:  R K Stoelting; P S Gibbs; C W Creasser; C Peterson
Journal:  Anesthesiology       Date:  1975-03       Impact factor: 7.892

9.  Plasma catecholamines in acute myocardial infarction.

Authors:  R A Nadeau; J de Champlain
Journal:  Am Heart J       Date:  1979-11       Impact factor: 4.749

10.  Neuroleptanalgesia in acute myocardial infarction: effects of hemodynamic parameters and plasma catecholamines.

Authors:  D Magometschnigg; H Hörtnagl; A Gassner; A F Hammerle; G Kleinberger; R Lenzhofer; H Lochs; H Pall; M Pichler
Journal:  Clin Cardiol       Date:  1981 Sep-Oct       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.